STAT+: A possible comeback for a failed sickle cell gene therapy

STAT reports that a sickle cell gene-editing therapy a decade in the making saw its trial end abruptly three years ago after the first patient suffered a serious adverse event. The outlet now suggests a possible comeback for the therapy, though the provided excerpt gives no further details.

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.